Welcome to our dedicated page for Medline SEC filings (Ticker: MDLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medline's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medline's regulatory disclosures and financial reporting.
GALANTI RICHARD A reported acquisition or exercise transactions in this Form 4 filing.
Medline Inc. director Richard A. Galanti reported stock-based compensation awards rather than open‑market purchases. He received 5,387 shares of Class A Common Stock as a grant at a price of $0.00 per share, bringing his direct holdings to 16,392 shares. Footnotes explain these are restricted stock units that vest either on March 30, 2027 or on the earlier of the first anniversary of grant and the next annual meeting of stockholders.
Sweet Thomas W reported acquisition or exercise transactions in this Form 4 filing.
Medline Inc. director Thomas W. Sweet reported equity awards rather than open‑market trades. On June 11, 2026, he received 5,387 shares of Class A Common Stock as a grant of restricted stock units at no cash cost, giving him 5,387 shares held directly after the grant.
The filing also reflects a prior award of 12,413 Class A shares on December 16, 2025, held indirectly through Mallard Advisory LLC, where he is a manager. Those restricted stock units vest on the earlier of the first anniversary of grant or the next annual stockholder meeting, illustrating standard director compensation in stock.
Medline Inc. director Todd M. Bluedorn reported stock-based compensation awards rather than open-market trades. He received 5,387 shares of Class A Common Stock on June 11, 2026 as a grant of restricted stock units (RSUs) that vest on the earlier of the first anniversary of grant or the next annual stockholder meeting. An earlier RSU grant of 10,345 shares on December 16, 2025 is also shown, vesting on March 30, 2027. Following the most recent award, he directly holds 15,732 shares of Medline Class A Common Stock, all acquired through grants.
Medline Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where all 12 director nominees were elected to one-year terms extending to the 2027 annual meeting. Each director received over 1.15 billion shares voted in favor, with additional broker non-votes recorded.
Stockholders also approved, on an advisory basis, the Company’s executive compensation, with 1,189,280,399 shares for and 6,203,145 against. In a separate advisory vote on how often to hold these say-on-pay votes, stockholders supported an annual frequency, and the Company decided to continue holding them every year.
Finally, stockholders ratified the selection of Ernst & Young LLP as Medline’s independent auditor for the fiscal year ending December 31, 2026, with 1,211,242,117 shares for, 156,205 against, and 47,637 abstentions.
Medline Inc. Principal Accounting Officer Jessi L. Corcoran reported an open-market purchase of Class A Common Stock. On June 5, 2026, Corcoran bought 5,000 shares at a price of $34.15 per share, bringing her directly held stake to 5,000 shares.
Medline Inc. outlines a major refinancing of its capital structure and a large secondary equity sale by existing investors. Indirect subsidiaries issued $1,250.0 million of 5.000% senior secured notes due 2031 and $750.0 million of 5.250% senior secured notes due 2033, both secured on a first‑lien basis and guaranteed by key domestic subsidiaries. The company also entered into a new $2,750.0 million senior secured term loan maturing in 2033, with 1.00% annual amortization and interest based on a base rate or Term SOFR plus an applicable margin. Net proceeds from the notes and the new term loan, together with cash on hand, were used to repay a 2028 term loan, refinance approximately $724.0 million of a 2030 term loan, and redeem approximately $500.0 million of 6.250% senior secured notes due 2029. Separately, selling stockholders affiliated with Blackstone, Hellman & Friedman and the Abu Dhabi Investment Authority completed an underwritten public offering of 72,554,594 Class A shares at $37.00 per share, with a 30‑day option for underwriters to buy up to an additional 10,883,189 shares.
Medline Inc. large shareholders affiliated with Hellman & Friedman reported significant open-market sales of Class A Common Stock alongside internal reallocations. On May 28, 2026, affiliated funds sold a combined 31,868,237 shares at an effective price of $36.5375 per share, reflecting the $37.00 secondary public offering price less a $0.4625 underwriting discount. The transactions were executed through an underwritten public offering, with sales attributed to entities including Hellman & Friedman Capital Partners X (Parallel), L.P., HFCP X (Parallel - A), L.P., Mend Partners II, L.P., and Mend Investment Holdings I, L.P. The filing also notes in-kind distributions of shares from certain funds to their ultimate partners and shareholders, and that distributed shares (other than a small charitable portion) are subject to a lock-up agreement with the underwriters.
Medline Inc. director Patrick J. Healy reported trust-related movements in Class A common stock, rather than open-market trading. A distribution in kind shifted shares previously held by investment funds into entities associated with the reporting person and a family trust.
After these J-code “other” transactions on the same date, 179,762 shares were held directly, 172,383 shares were held indirectly through a family trust, and 39,189 shares were held indirectly through a children’s trust. The filing notes that Healy disclaims beneficial ownership of trust-held shares beyond his pecuniary interest.
Medline Inc. reported that investment vehicles affiliated with Blackstone reduced part of their indirect stake in the company. On May 28, 2026, these entities sold an aggregate of 33,317,824 shares of Class A common stock in connection with a secondary offering at about $36.5375 per share, the public price net of underwriting discounts. The filing also shows a J-code in-kind distribution of 438,214 shares from Mozart Aggregator II LP to one of its investors and related entities, which remain subject to lock-up restrictions. Despite these sales and distributions, affiliated entities continue to hold large indirect positions, including 89,537,913 shares of Class A common stock after the reported transactions.